Navigation Links
DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
Date:4/21/2013

PARSIPPANY, N.J., April 22, 2013 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USAThe agreement covers the initiation of development activities by DSM for DecImmune's lead monoclonal antibody program. The initial development will be performed at DSM Biologics' Groningen, the Netherlands, facility, with the objective of progressing manufacture of clinical trial material to DSM's facility in Brisbane, Australia. DecImmune's proprietary antibody therapeutic is designed to reduce tissue damage and improve ventricular function associated with myocardial infarction. Regaining full function after a heart attack can be complicated by irreversible tissue damage and scar formation that leads to a significant loss in cardiac pumping efficiency. In a range of experimental models, DecImmune has shown that it is possible to reduce damage to heart tissue by using their proprietary therapeutic antibody. In these models the reduction in damage to heart tissue results in pumping efficiency returning to normal levels. DecImmune is also investigating this targeted approach to reduce tissue damage for a range of other acute and chronic post-injury settings.

Karen King , President of DSM Biologics, commented "We are delighted to be working with DecImmune on their exciting project.  DSM is committed to delivering our clients around the world the highest quality solutions and services." DSM Biologics, a business unit of DSM Pharmaceutical Products, focuses on optimizing mammalian-based biopharmaceutical manufacturing through its unique set of technologies and expertise. In addition to an R&D and manuf
'/>"/>

SOURCE DSM Pharmaceutical Products
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
2. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
3. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
4. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
5. Sorbent Therapeutics Initiates Phase 2b Clinical Trial of CLP-1001 for Treatment of Signs and Symptoms of Fluid Overload in Patients with Heart Failure
6. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
7. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
8. Spencer Trask Congratulates InVivo Therapeutics on its Recent Approvals from the FDA
9. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
10. Adenosine Therapeutics Engages Needham & Company to Explore Strategic Options for Phase III Cardiac Stress Agent
11. Halozyme Therapeutics Names Matt Posard to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 2015  IRIDEX Corporation (Nasdaq: IRIX ) today ... granted the Company a patent for a new proprietary ... eye surgery. The iClip Closure Device will initially be ... a broader range of ophthalmic surgical procedures in the ... procedure used in the treatment of glaucoma to drain ...
(Date:3/29/2015)... , March 29, 2015  Three-month paliperidone palmitate, ... relapse compared to placebo in patients with schizophrenia, ... published this week in the Journal ... . Results of the study served ... Application (NDA) filing for three-month paliperidone palmitate injection ...
(Date:3/27/2015)... NEW YORK , March 27, 2015 ... of Ohr Pharmaceutical, Inc. (NASDAQ: OHRP ) concerning ... certain statements issued by the Company in connection with ... information, GO TO: http://zlk.9nl.com/ohr-pharmaceutical-ohrp or contact ... jlevi@zlk.com or by telephone at (212) 363-7500, ...
Breaking Medicine Technology:IRIDEX Granted U.S. Patent for Disposable Device for Efficient and Predictable Wound Closure in Eye Surgeries 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 ... promotion on Invisalign. Eligible patients will receive $200 off ... are not particularly interested in wearing a mouthful of ... team, “The use of traditional braces is effective for ... who are already concerned with their oral appearance. The ...
(Date:3/30/2015)... Valerie Harper, the actress best known as ... Mary Tyler Moore Show,” will be the keynote speaker ... magazine announced today. Harper, who is living with terminal ... 40th Annual Congress on April 23 in Orlando, Fla. ... play in the lives of people with cancer. Nominated ...
(Date:3/30/2015)... 2015 GenSight ®, provider of ... as a leader in The Forrester Wave™: Strategic Planning ... , The independent report positions GenSight as a leader ... out of 5) for the analytics, corporate strategy, assessment, ... to GenSight’s position in the Leaders category. , According ...
(Date:3/30/2015)... 30, 2015 In an email sent ... of Oak Ridge, TN Community Development Department, announced: “I ... to traditional LBP work”. , ECOBOND® ... lead paint solution and surpasses other lead paint products ... that seals and treats lead dust and lead in ...
(Date:3/30/2015)... Software applications from five global ... second AS4 test and certification event, announced today ... interoperability software testing. New software applications from Axway, ... in this vendor-neutral test event which began in ... certifications for IBM, Oracle and Software AG, joining ...
Breaking Medicine News(10 mins):Health News:Northridge Cosmetic Dentist, Dr. Arami, is Now Offering a New Promotion on Invisalign 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 2Health News:Spunky Sitcom Star and Lung Cancer Survivor Valerie Harper to Keynote Extraordinary Healer™ Award Ceremony Honoring Oncoloy Nurses 3Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:ECOBOND® Selected to Protect School Children in Oak Ridge Tennessee in Lead Based Paint Remediation Project. 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 2Health News:Latest AS4 Standard-Based Products Drummond Certified™ 3
... , , , , ... 21 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported ... total revenue of $209.4 million for the quarter ended June 30, 2009, ... charge of $11.4 million associated with the Company,s sales force reduction in ...
... , , ALISO VIEJO, Calif., July ... that it will host a conference call and a live Internet webcast ... a.m. EDT (7:00 a.m. PDT) to discuss results for the 2009 second ... participate on this call is (877) 295-5743, confirmation code 20797641. International ...
... First three cases of likely HIV transmission to infants ... against pre - chewing food; also a ... Tenn., July 21 Researchers have uncovered the first cases in ... through pre-chewed food. The source of HIV in the pre-chewed food was most ...
... , SALT LAKE CITY, July 21 Health ... its innovative features, most notably its ability to save exercise data ... account to track progress. The LifeSpan TR4000i treadmill, made by PCE ... as judged by experts from Health magazine. The Best Treadmill award ...
... American men could be putting their health at risk ... results might threaten their masculinity. Because they prove their ... advice including HIV/AIDS testing goes against their notion of ... Department of Sociology at Yale University in the US, ...
... , NEW YORK, July 21 ... research teams at nine biotech and pharmaceutical companies a total ... investigations aim to push forward novel neuroprotective and improved symptomatic ... treatment. , , While MJFF ...
Cached Medicine News:Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Amylin Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009 2Health News:Pre-chewed Food Could Transmit HIV 2Health News:Pre-chewed Food Could Transmit HIV 3Health News:Pre-chewed Food Could Transmit HIV 4Health News:LifeSpan Treadmill Awarded BEST TREADMILL by Health Magazine 2Health News:'Go to the doctor? Only if I'm really sick ...' 2Health News:Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development 2Health News:Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinson's Drug Development 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: